首页> 外文期刊>Current rheumatology reports. >Tissue-Engineering Strategies to Repair Chondral and Osteochondral Tissue in Osteoarthritis: Use of Mesenchymal Stem Cells
【24h】

Tissue-Engineering Strategies to Repair Chondral and Osteochondral Tissue in Osteoarthritis: Use of Mesenchymal Stem Cells

机译:修复骨关节炎中软骨和骨软骨组织的组织工程策略:间充质干细胞的使用

获取原文
获取原文并翻译 | 示例
       

摘要

Focal chondral or osteochondral lesions can be painful and disabling because they have insufficient intrinsic repair potential, and constitute one of the major extrinsic risk factors for osteoarthritis (OA). Attention has, therefore, been paid to regenerative therapeutic procedures for the early treatment of cartilaginous defects. Current treatments for OA are not regenerative and have little effect on the progressive degeneration of joint tissue. One major reason for this under-representation of regenerative therapy is that approaches to treating OA with cell-based strategies have to take into consideration the larger sizes of the defects, as compared with isolated focal articular-cartilage defects, and the underlying disease process. Here, we review current treatment strategies using mesenchymal stem cells (MSCs) for chondral and osteochondral tissue repair in trauma and OA-affected joints. We discuss tissue-engineering approaches, in preclinical large-animal models and clinical studies in humans, which use crude bone-marrow aspirates and MSCs from different tissue sources in combination with bioactive agents and materials.
机译:局灶性软骨或骨软骨病变可能会造成疼痛和致残,因为它们的内在修复潜能不足,并且是骨关节炎(OA)的主要外在危险因素之一。因此,已经注意到用于软骨缺陷的早期治疗的再生治疗方法。当前的OA治疗不能再生,并且对关节组织的进行性退化几乎没有影响。再生疗法这种代表性不足的一个主要原因是,与孤立的局灶性关节软骨缺损相比,采用基于细胞的策略治疗OA的方法必须考虑到较大的缺损,以及潜在的疾病过程。在这里,我们回顾了使用间充质干细胞(MSC)修复创伤和骨关节炎影响的关节的软骨和骨软骨组织的当前治疗策略。我们在临床前大动物模型和人类临床研究中讨论组织工程方法,这些方法将来自不同组织来源的粗骨髓抽吸物和MSC与生物活性剂和材料结合使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号